Vanderbilt University
Jennifer A. Pietenpol, Ph.D.
691 Preston Research Building
Nashville, Tennessee 37232-6838
Tel: (615) 936-1782
Fax: (615) 936-1790
Information on Vanderbilt-Ingram Cancer Center
The Vanderbilt-Ingram Cancer Center (VICC) is committed to assembling the best and brightest scientists, clinicians, and caregivers to lead the ongoing effort to alleviate suffering from cancer through pioneering research, compassionate care, and prevention. The VICC was established in 1993 as the umbrella organization over cancer-related research, clinical care and education at the Vanderbilt University Medical Center in Nashville, Tenn. The VICC In 1995, it became a National Cancer Institute-designated cancer center and, in 2001, the only NCI-designated Comprehensive Cancer Center in Tennessee. Vanderbilt-Ingram emphasizes individualized cancer care developed and delivered through a comprehensive, multidisciplinary team approach, with particular strengths in lung, GI, breast, and head and neck cancers, as well as melanoma and sarcoma. The activities of the VICC are anchored in the Frances Williams Preston Building and include the Henry-Joyce Cancer Clinic, inpatient units in Vanderbilt Hospital and more than 120 laboratories throughout the University and Medical Center. Pediatric cancer care is delivered in the freestanding Monroe Carell Jr. Children’s Hospital at Vanderbilt, listed among the top 10 children’s hospitals in the country. The clinical volume of the VICC has increased steadily over the years now reaching more than 40,000 outpatient visits annually with enrollment of more than 7,500 patients into clinical trials since 1998. Vanderbilt-Ingram offers more than 200 clinical trials for adults and children at its main campus and through 15 members of its Affiliate Network throughout Tennessee, Kentucky and Georgia.
Its research enterprise emphasizes translational research and builds on a strong legacy of basic science in growth factors and signal transduction. It includes seven formal research programs covering the areas of signal transduction and cell proliferation; host-tumor interaction; gastrointestinal cancer; breast cancer; genomics and proteomics; cancer prevention and control; and experimental therapeutics. Since its inception, competitive NCI grant funding has grown more than six-fold to more than $50 million per year; total annual research funding including private sources tops $130 million. Vanderbilt-Ingram is home to three Specialized Programs of Research Excellence (SPOREs) in breast, gastrointestinal and lung cancers, a Digestive Disease Center, a Mouse Models of Human Cancer Consortium grant, a Molecular Signatures in Lung Cancer grant, several cohort grants, including the Southern Community Cohort Study, and in collaboration with Meharry Medical College, an NCI partnership grant to address racial and regional disparities in cancer incidence and mortality.

Vanderbilt-Ingram Cancer Center is proud to be among only 40 in the United States that are designated as Comprehensive Cancer Centers by the National Cancer Institute, the world’s foremost authority on cancer. We are the only NCI-designated Comprehensive Cancer Center in Tennessee that treats all cancer types and patients of all ages.

Since 2007, Vanderbilt-Ingram has also been a member of National Comprehensive Cancer Network (NCCN). This network of the world’s leading cancer centers have joined together to develop the guidelines for care that other oncologists follow and to improve the effectiveness and quality of care for patients everywhere.

Centers in these elite groups consult with each other and, when a patient’s case suggests it, refer to one another. After all, cancer is the competition.

Make an Appointment
Phone our hotline 24 hours/daay, 7 days/week locally at 615-936-VICCC (8422) or toll free 1-877-936-VICCC (8422)
For Cancer Clinical Trials, call our Cancer Information Progran at 1-800-811-8400.
*Source: National Cancer Institute

Leave a Comment